Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Lemieux B is active.

Publication


Featured researches published by Lemieux B.


Canadian Journal of Neurological Sciences | 1976

Clinical Description and Roentgenologic Evaluation of Patients with Friedreich's Ataxia

Barbeau A; Breton G; Lemieux B; M. Aube; C. Leger; J.P. Bouchard

The 50 patients in this survey were classified by a panel of neurologists into 4 clinical sub-groups: Group Ia (typical Friedreichs ataxia, complete picture), Group Ib (typical Friedreichs ataxia, incomplete picture), Group IIa (atypical Frriedreichs ataxia, possible recessive Roussy-Levy syndrome), Group IIb (heterogeneous ataxias). The clinical symptoms and signs were analyzed for each of these groups. A constellation of signs constantly present in Friedreichs ataxia and obligatory for diagnosis was described. Other important symptoms, such as the Babinski sign, kyphoscoliosis and pes cavus were found to be progressive, but not essential for the diagnosis at any given time. Finally, a host of other symptoms can only be called accessory. The progression of scoliosis was found to be an important tool in the differential diagnosis of ataxias. Our study also indicates, in contrast to the opinion of some authors, that absent deep tendon reflexes in the lower limbs and early dysarthria are essential in typical Friedreichs ataxia.


Canadian Journal of Neurological Sciences | 1976

Pyruvate metabolism in Friedreich's ataxia.

Barbeau A; Butterworth Rf; Ngo T; Breton G; Serge B. Melançon; Dennis Shapcott; Lemieux B

Friedreichs ataxia patients show evidence of an abnormally elevated and prolonged response of pyruvate and lactate to a glucose load, with normal fasting levels. However, ther is a bimodal distribution of this response with high and low pyruvate responders. This trait appears to be determined genetically, However, although in vivo tests suggest low oxidation of pyruvate, we were unable to confirm any in vitro impairment of each of the components of the pyruvate dehydrogenase (PDH) complex. We conclude that the defect is in the metabolic regulation of PDH, probably at the E3 (lipoamide dehydrogenase) step.


Canadian Journal of Neurological Sciences | 1976

Glucose and insulin metabolism in Friedreich's ataxia.

Dennis Shapcott; Serge B. Melançon; Butterworth Rf; Khoury K; Collu R; Breton G; Lemieux B; Barbeau A

Our prospective survey of 50 ataxic patients confirms the previous finding of frequent clinical or chemical diabetes in Friedreichs ataxia. Eighteen percent of our typical cases have clinical diabetes and 40% at least an abnormal glucose tolerance curve. However, this finding does not appear to be specific to that form of ataxia. Furthermore, we have shown that most patients with ataxia have normal or low fasting insulin levels, but a hyperinsulinic response to a glucose load.


Canadian Journal of Neurological Sciences | 1976

Amino acid metabolism in Friedreich's ataxia.

Lemieux B; Barbeau A; Beroniade; Dennis Shapcott; Breton G; Serge B. Melançon

A study of amino acids determined by sequential Multi-sample Amino Acid Automatic Analyzer in plasma, urine and cerebrospinal fluid (CSF) in patients with Friedreichs ataxia and control subjects has revealed a number of mathematically significant variations from normal. Of practical physiological importance are the following: a high urinary excretion of alanine with slightly elevated plasma levels; a low plasma and CSF concentration of aspartic acid in the presence of normal urinary values and finally a low CSF concentration of taurine accompanied by normal plasma levels, but elevated urinary output and renal clearance rates. We postulate that the modifications in alanine and aspartic acid are less specific and probably secondary, but there could be a genetic defect in the membrane transport of taurine and the other beta-amino acids in Friedreichs ataxia.


Pediatric Neurology | 2017

Epidemiology and Outcomes of Arterial Ischemic Stroke in Children: The Canadian Pediatric Ischemic Stroke Registry

Gabrielle deVeber; Adam Kirton; Frances A. Booth; Jerome Y. Yager; Elaine C. Wirrell; Ellen Wood; Michael Shevell; Ann Marie Surmava; Patricia McCusker; M. Patricia Massicotte; Daune MacGregor; E. Athen MacDonald; Brandon Meaney; Simon Levin; Lemieux B; Lawrence Jardine; Peter Humphreys; Michèle David; Anthony K.C. Chan; David Buckley; Bruce Bjornson

BACKGROUNDnPediatric arterial ischemic stroke remains incompletely understood. Population-based epidemiologicalxa0data inform clinical trial design but are scant in this condition. We aimed to determine age-specific epidemiologicalxa0characteristics of arterial ischemic stroke in neonates (birth to 28xa0days) and older children (29xa0days to 18xa0years).nnnMETHODSnWe conducted a 16-year, prospective, national population-based study, the Canadian Pediatric Ischemic Stroke Registry, across all 16 Canadian acute care childrens hospitals. We prospectively enrolled children with arterial ischemic stroke from January 1992 to December 2001 and documented disease incidence, presentations, risk factors, and treatments. Study outcomes were assessed throughout 2008, including abnormal clinical outcomes (stroke-related death or neurological deficit) and recurrent arterial ischemic stroke or transient ischemic attack.nnnRESULTSnAmong 1129 children enrolled with arterial ischemic stroke, stroke incidence was 1.72/100,000/year, (neonates 10.2/100,000 live births). Detailed clinical and radiological information were available for 933 children (232 neonates and 701 older children, 55% male). The predominant clinical presentations were seizures in neonates (88%), focal deficits in older children (77%), and diffuse neurological signs (54%) in both. Among neonates, 44% had no discernible risk factors. In older children, arteriopathy (49% of patients with vascular imaging), cardiac disorders (28%), and prothrombotic disorders (35% of patients tested) predominated. Antithrombotic treatment increased during the study period (Pxa0<xa00.001). Stroke-specific mortality was 5%. Outcomes included neurological deficits in 60% of neonates and 70% of older children. Among neonates, deficits emerged during follow-up in 39%. Overall, an initially decreased level of consciousness, a nonspecific systemic presentation, and the presence of stroke risk factors predicted abnormal outcomes. For neonates, predictors were decreased level of consciousness, nonspecific systemic presentation, and basal ganglia infarcts. For older children, predictors were initial seizures, nonspecific systemic presentation, risk factors, and lack of antithrombotic treatment. Recurrent arterial ischemic stroke or transient ischemic attack developed in 12% of older children and was predicted by arteriopathy, presentation without seizures, and lack of antithrombotic treatment. Emerging deficit was predicted by neonatal age at stroke and by cardiac disease.nnnCONCLUSIONSnThis national data set provides a population-based disease incidence rate and demonstrates the protective effect of antithrombotic treatment in older children, and frequent long-term emerging deficits in neonates and in children with cardiac disorders. Further clinical trials are required to develop effective age-appropriate treatments for children with acute arterial ischemic stroke.


Clinical Biochemistry | 1979

Rapid thin-layer chromatographic method for the detection of urinary methylmalonic acid.

Christiane Auray-Blais; Daniel Paradis; Lemieux B

1. Simple and rapid thin-layer and micro-thin-layer chromatography techniques are described for the detection of methylmalonic acid in urine. 2. The separation of methylmalonic acid from a crude urine sample is performed by thin-layer chromatography with a mixture of silica gel-cellulose and butanol - acetic acid - water solvent system. The methylmalonic acid spot is visualized with tetrazotized o-dianisidine. 3. This system has been successfully developed for a urinary screening programme; it was shown as simple, convenient and rapid, eliminating false-positives and allowing the detection of even traces of methylmalonic acid.


Canadian Journal of Neurological Sciences | 1979

Erythrocyte membrane lipids in Friedreich's ataxia.

P. Draper; Y.S. Huang; Dennis Shapcott; Lemieux B; M. Brennan; Barbeau A; J. Davignon

In a study of the lipid composition of erythrocyte membranes in Friedreichs ataxia, the concentration of the major membrane components (phospholipids, cholesterol and protein) in ataxic patients, family members, and control subjects were found to be the same. The total fatty acid distribution was also normal. However, an altered distribution of phospholipid classes in erythrocytes was noted (an increase of PI + PS and a decrease of PE in Friedreichs ataxia patients).


Canadian Journal of Neurological Sciences | 1979

Regulation of respiration in Friedreich's ataxia.

Raymond Bégin; L. Lupien; M. A. Bureau; J. Labbe; Lemieux B

Friedreichs Ataxia (F.A.) is a degenerative disease which commonly leads to premature death of cardiorespiratory origin. To explain the early death of these patients, previous investigations have established the existence of 1) a cardiomyopathy in nearly 100% of cases, 2) a restrictive pulmonary syndrome of scoliotic origin and 3) a mild hypoxemia associated with slight respiratory alkalosis and a normal oxyhemoglobin dissociation curve. To further assess the cause of early death in patients with such neuromyopathy, we evaluated, in eleven F.A. patients, the sensitivity of the respiratory centers to hypercapnia, hypoxia, and hyperoxia. Ventilatory (VE, VT, F, VT/Ti) and occlusion pressure (P0.1) responses were taken as indices of the respiratory centers output during progressive hypercapnia (Reads method) and isocarbic hypoxia (Weils method). We studied 11 Friedreichs Ataxia patients and 11 age, sex, and armspan matched controls. The responses of patients to hypercapnia were significantly greater than controls but their responses to hypoxia were similar to controls. Our study establishes that the respiratory centers are functioning adequately in early Friedreichs Ataxia and do not contribute to cardio-respiratory insufficiency in such neuromyopathy.


Canadian Journal of Neurological Sciences | 1978

Platelet taurine uptake in spinocerebellar degeneration.

Filla A; Butterworth Rf; Lemieux B; Barbeau A

The uptake of 14C-taurine was studied in the platelets of 20 ataxic patients and 20 age-matched normal control subjects. No significant differences were found in uptake or kinetics of taurine between the two groups of subjects. If a transport defect in taurine exists in Friedreichs ataxia, it is not present in all tissues. Preliminary indication was obtained in favor of heterogenity of the uptake pattern between ataxic individuals.


Canadian Journal of Neurological Sciences | 1978

Taurine in cerebrospinal fluid in Friedreich's ataxia.

Lemieux B; Barbeau A; Melancon S; Dennis Shapcott

In a previous study we reported low values of taurine and aspartic acid in the CSF of patients with Friedreichs ataxia, when the results were compared to the literature. Further studies have revealed that unforetold difficulties with the advertised methodology of sequential multi-sample amino acid analysis were responsible for low values in the determination of these two amino acids in the small volumes necessary for CSF. A corrected method is presented. With the latter method the differences disappear for CSF taurine and aspartic acid, but they remain valid for the previously reported blood and urine values in Friedreichs ataxia. GABA levels are also normal in Friedreichs ataxia CSF.

Collaboration


Dive into the Lemieux B's collaboration.

Top Co-Authors

Avatar

Dennis Shapcott

Université de Sherbrooke

View shared research outputs
Top Co-Authors

Avatar

Barbeau A

Université de Sherbrooke

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Denis Cyr

Université de Sherbrooke

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Daniel Paradis

Université de Sherbrooke

View shared research outputs
Top Co-Authors

Avatar

Patrick Draper

Université de Sherbrooke

View shared research outputs
Top Co-Authors

Avatar

Raymond Bégin

Université de Sherbrooke

View shared research outputs
Top Co-Authors

Avatar

Régen Drouin

Université de Sherbrooke

View shared research outputs
Researchain Logo
Decentralizing Knowledge